Gene therapy for infectious diseases

Clinical Microbiology Reviews

Volumn 11, Issue 1, 1998, Pages 42-56

  Bunnell, Bruce A ^a,b   Morgan, Richard A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DNA VACCINE; NUCLEIC ACID; PROTEIN; RIBOZYME;

CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GENE THERAPY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; IMMUNOTHERAPY; INFLUENZA VIRUS; LIFE CYCLE; NONHUMAN; PATIENT CARE; REVIEW; SUICIDE GENE; VIRUS INFECTION; WART VIRUS;

CYTOMEGALOVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPES; INFLUENZA VIRUS; SIMPLEXVIRUS;

EID: 0031984458     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.11.1.42     Document Type: Review

References (166)

1. Agrawal, S., and J. Y. Tang. 1992. GEM 91 - an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res. Dev. 2:261-266.
2. Aguilar-Cordova, E., J. Chinen, L. A. Donehower, J. W. Harper, A. P. Rice, J. S. Butel, and J. W. Belmont. 1995. Inhibition of HIV-1 by a doubletransdominant fusion gene. Gene Ther. 2:181-186.
3. Alt, M., R. Ring, P. H. Hofschneider, G. Paumgartner, and W. H. Caselmann. 1995. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 22:707-717.
4. Anderson, W. F. 1992. Human gene therapy. Science 256:808-813.
5. Azad, R. F., V. B. Driver, K. Tanaka, R. M. Cooke, and K. P. Anderson. 1993. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37:1945-1954.
6. Bahner, I., C. Zhou, X. J. Yu, Q. L. Hao, J. C. Guatelli, and D. B. Kohn. 1993. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J. Virol. 67:3199-3207.
7. Baltimore, D. 1988. Intracellular immunization. Nature 335:395-397.
8. 2;,-interferon. Proc. Natl. Acad. Sci. USA 86:4958-4962.
9. Berger, E. A., T. R. Fuerst, and B. Moss. 1988. A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 85:2357-2361.
10. Bevec, D., H. Jaksche, M. Oft, T. Wohl, M. Himmelspach, A. Pacher, M. Schebesta, K. Koettnitz, M. Dobrovnik, R. Csonga, F. Lottspeich, and J. Hauber. 1996. Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A. Science 271:1858-1860.
11. Bogerd, H., and W. C. Greene. 1993. Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo. J. Virol. 67:2496-2502.
12. Bordier, B., C. Helena, P. J. Barr, S. Litvak, and L. Sarih-Cottin. 1992. In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription. Nucleic Acids Res. 20:5999-6006.
13. Bourne, N., G. N. Milligan, M. R. Schleiss, D. I. Bernstein, and L. R. Stanberry. 1996. DNA immunization confers immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 14:1230-1234.
14. Bourne, N., L. R. Stanberry, D. I. Bernstein, and D. Lew. 1996. DNA immunization against experimental genital herpes simplex virus infection. J. Infect. Dis. 173:800-807.
15. Breaker, R. R., and G. F. Joyce. 1994. Inventing and improving ribozyme function: rational design versus iterative selection methods. Trends Biotechnol. 12:268-275.
16. Bryant, L. A., and J. H. Sinclair. 1993. Inhibition of human cytomegalovirus major immediate-early gene expression by antisense RNA expression vectors. J. Virol. 74:1965-1967.
17. Buchschacher, G. L., E. O. Freed, and A. T. Panganiban. 1992. Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. Hum. Gene Ther. 3:391-397.
18. Buonocore, L., and J. K. Rose. 1990. Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum. Nature 345:625-628.
19. + T cells by an intracellular CD4 expressed under control of the viral long terminal repeat. Proc. Natl. Acad. Sci. USA 90:2695-2699.
20. Burke, J. M. 1996. Hairpin ribozyme: current status and future prospects. Biochem. Soc. Trans. 24:608-615.
21. + cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc. Natl. Acad. Sci. USA 89:182-186.
22. Chada, S., C. E. Dejesus, K. Townsend, W. T. Lee, L. Laube, D. J. Jolly, S. M. W. Chang, and J. F. Warner. 1993. Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes. J. Virol. 67:3409-3417.
23. Chatterjee, S., P. R. Johnson, and K. K. Wong. 1992. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science 258:1485-1488.
24. Chen, C. J., A. C. Banerjea, G. G. Harrison, K. Haglund, and M. Shubert. 1992. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20:4581-4589.
25. Chen, S. Y., J. Bagley, and W. A. Marasco. 1994. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum. Gene Ther. 5:595-601.
26. Chen, Z., P. Kamath, S. Zhang, M. M. Weil, and E. J. Shillitoe. 1995. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus 18. Cancer Gene Ther. 2:263-271.
27. Chen, Z., P. Kamath, S. Zhang, L. St. John, K. Alder-Story, and E. J. Shillitoe. 1996. Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Ther. 3:18-23.
28. Chuah, M. K. L., T. VandenDriessche, H. K. Chang, B. Ensoli, and R. A. Morgan. 1994. Inhibition of human immunodeficiency virus type-I by retroviral vectors expressing antisense TAR. Hum. Gene Ther. 5:1467-1475.
29. Cowsert, L. M., M. C. Fox, G. Zon, and M. K. Mirabelli. 1993. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob. Agents Chemother. 37:171-177.
30. Culmann, B., E. Gomard, M. P. Kieny, B. Guy, F. Dreyfus, A. G. Saimost, D. Sereni, and J. P. Levy. 1990. An antigen peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules. Eur. J. Immunol. 19:2383-2386.
31. Culver, K. W., Z. Ram, S. Walbridge, H. Ishii, E. H. Oldfield, and R. M. Blaese. 1992. In vivo gene transfer with retroviral-vector producer cells for the treatment of experimental brain tumors. Science 256:1550-1552.
32. Daar, E. S., X. L. Li, T. Moudgil, and D. D. Ho. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 87:6574-6578.
33. Daar, E. S., and D. D. Ho. 1991. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. Am. J. Med. 90:22S-26S.
34. Dal Mante, P., C. Bessia, A. Ripalti, M. P. Landini, A. Topilko, B. Plachter, J. L. Virelizier, and S. Michelson. 1996. Stably expressed antisense RNA to cytomegalovirus UL83 inhibits viral replication. J. Virol. 70:2086-2094.
35. Davis, H. L., M. J. McCluskie, J. L. Gerin, and R. H. Purcell. 1996. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. USA 93:7213-7218.
36. Deen, C. D., J. S. McDougal, R. Inacker, G. Folena-Wasserman, J. Arthos, J. Rosenberg, P. J. Maddon, R. Axel, and R. W. Sweet. 1988. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 331:82-84.
37. Donnelly, J. J., A. Friedman, D. Martinez, D. L. Montgomery, J. W. Shiver, S. L. Motzel, J. B. Ulmer, and M. A. Liu. 1995. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1:583-587.
38. Dropulic, B., N. H. Lin, M. A. Martin, and K. T. Jeang. 1992. Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J. Virol. 66:1432-1441.
39. Duan, L., O. Bagasra, M. A. Laughlin, J. W. Oakes, and R. J. Pomerantz. 1994. Potent inhibition of human immunodeficiency virus type 1 by an intracellular anti-Rev single-chain antibody. Proc. Natl. Acad. Sci. USA 91:5075-5079.
40. Esaich, S., C. Kalfoglou, I. Plavec, S. Kaushal, J. D. Mosca, and E. Bohnlein. 1995. RevM10-mediated inhibition of HIV-1 replication in chronically infected T-cells. Hum. Gene Ther. 6:625-634.
41. Feinberg, M. B., and D. Trono. 1992. Intracellular immunization: transdominant mutants of HIV gene products as tools for the study and interruption of viral replication. AIDS Res. Hum. Retrovirus 8:1013-1022.
42. Fisher, R. A., J. M. Bertonis, W. Meier, V. A. Johnson, D. S. Costopoulos, T. Liu, R. Tizard, B. D. Walker, M. S. Hrisch, R. T. Schooley, and R. A. Flavell. 1988. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 331:76-78.
43. Gao, M., and D. M. Knipe. 1991. Potential role for herpes simplex virus ICP8 DNA replication protein in stimulation of late gene expression. J. Virol. 65:2666-2675.
44. Gervaix, A., X. Li, G. Kraus, and F. Wong-Staal. 1997. Multigenc antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J. Virol. 71:3048-3053.
45. Goodarzi, G., S. C, Gross, A. Tewari, and K. Watabe. 1990. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J. Gen. Virol. 71:3021-3025.
46. Green, M., M. Isbino, and P. M. Loewenstein. 1989. Mutational analysis of HIV-1 tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58:215-223.
47. Greenberg, P. D., B. Nelson, M. Gilbert, A. Sing, C. Yee, M. Jensen, and S. R. Riddell. 1994. Vaccines against virally induced cancers, p. 212-228. John Wiley & Sons, Ltd., Chichester, United Kingdom.
48. Hanecak, R., V. Brown-Driver, M. C. Fox, R. F. Azad, S. Furusako, C. Nozaki, C. Ford, H. Sasmor, and K. P. Anderson. 1996. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol. 70:5203-5212.
49. Harrison, G. S., C. J. Long, T. J. Curiel, F. Maxwell, and I. H. Maxwell. 1992. Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. Hum. Gene Ther. 3:461-469.
50. Herskowitz, I. 1987. Functional inactivation of genes by dominant negative mutations. Nature 329:219-222.
51. Heslop, H. E., M. K. Brenner, C. Rooney, R. A. Krance, W. M. Roberts, R. Rochester, C. A. Smith, V. Turner, J. Sixbey, and R. Moen. 1994. Administration of neomycin-resistance-gene-marked EBV specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum. Gene Ther. 5:381-397.
52. Hope, T. J., N. P. Klein, M. E. Elder, and T. G. Parslow. 1992. Transdominant inhibition of human immunodeficiency virus type 1 rev occurs through formation of inactive protein complexes. J. Virol. 66:1849-1855.
53. Huber, B. E., E. A. Lustin, S. S. Good, V. C. Knick, S. Tibbels, and C. A. Richards. 1993. In vivo tumor activity of 5-flurocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53:4619-4626.
54. Hussey, R. E., N. E. Richardson, M. Kowalski, N. R. Brown, H. C. Chang, R. F. Siliciano, T. Dorfman, B. Walker, J. Sodroski, and E. L. Reinherz. 1988. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 331:84-86.
55. Husson, R. N., Y. Chung, J. Mordenti, K. M. Butler, S. Chen, A. M. Duliege, P. Brouwers, P. Jarosinski, B. U. Mueller, and A. Ammann. 1992. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection. J. Pediatr. 121:627-633.
56. Huygen, K., J. Content, O. Denis, D. L. Montgomery, A. M. Yawman, R. R. Deck, G. M. DeWitt, I. M. Orme, S. Baldwin, C. D'Souza, A. Drowant, E. Lozes, P. Vandenbussche, J. P. VanVooren, M. A. Liu, and J. B. Ulmer. 1996. Immunogenicity and protective efficacy of tuberculosis DNA vaccine. Nat. Med. 2:893-898.
57. Irwin, M. J., L. S. Laube, V. Lee, M. Austin, S. Chada, C. G. Anderson, K. Townsend, D. J. Jolly, and J. Warner. 1994. Direct injection of recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates. J. Virol. 68:5036-5044.
58. Jolly, D., S. Chada, K. Townsend, C. E. De Jesus, S. Chang, K. Weinhold, C. G. Anderson, A. Lynn, M. Bodner, and J. Barber. 1992. CTL cross reactivity between HIV strains. AIDS Res. Hum. Retroviruses 8:1369-1371.
59. Jolly, D. J., and J. F. Warner. 1991. Induction of an anti-HIV-1 immune responses by retroviral vectors. Biotechnol. Ther. 2:179-193.
60. Joshi, S., A. Van Brunschot, S. Asad, et al. 1991. Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression. J. Virol. 65:5524-5530.
61. Kean, J. M., S. A. Kipp, P. S. Miller, M. Kulka, and L. Aurelian. 1995. Inhibition of herpes simplex virus replication by antisense oligo-2′-O-methylribonucleoside methylphosphonates. Biochemistry 34:14617-14620.
62. Kinchington, D., S. Galpin, J. Jaroszewski, K. Ghosh, C. Subashinghe, and J. S. Cohen. 1992. A comparison of gag, pol, and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antiviral Res. 17:53-62.
63. Kubota, S., R. Furuta, M. Maki, and M. Hatanaka. 1992. Inhibition of human immunodeficiency virus type 1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev. J. Virol. 66:2510-2513.
64. Kundu, S. K., and T. C. Merigan. 1991. Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV-infection. Immunology 74:567-571.
65. Laube, L. S., M. Burrascano, C. E. De Jesus, B. D. Howard, M. A. Johnson, W. T. Lee, A. E. Lynn, G. Peters, G. S. Ronlov, and K. S. Townsend. 1994. Cytotoxic T lymphocytes and antibody responses generated in rhesus monkeys immunized with retroviral-vector transduced fibroblasts expressing HIV-1 IIIB env/rev proteins. Hum. Gene Ther. 5:853-862.
66. Leavitt, M. C., M. Yu, O. Yamada, G. Kraus, D. Looney, E. Poeschla, and F. Wong-Staal. 1994. Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum. Gene Ther. 5:1115-1120.
67. Lee, P. P., and M. L. Linial. 1995. Inhibition of wild-type HIV-1 virus production by a matrix deficient Gag mutant. Virology 208:808-811.
68. Lee, S. W., H. F. Gallardo, E. Gilboa, and C. Smith, 1994. Inhibition of human immunodeficiency virus in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J. Virol. 68:8254-8264.
69. Lee, T. C., B. A. Sullenger, H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1992. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol. 4:66-74.
70. Lieberman, J., J. A. Fabry, P. Shankar, L. Beckett, and P. R. Skolnick. 1995. Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res Hum. Retroviruses 11:257-272.
71. Liem, S. E., A. Ramezani, X. Li, and S. Joshi. 1993. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum. Gene Ther. 4:625-634.
72. Lisziewicz, J., J. Rappaport, and R. Dhar. 1991. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol. 3:82-89.
73. Lisziewicz, J., D. Sun, M. Klotman, S. Agrawal, P. Zamencik, and R. C. Gallo. 1992. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc. Natl. Acad. Sci. USA 89:11209-11213.
74. Lisziewicz, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi. M. Reitz, and R. C. Gallo. 1993. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy for AIDS. Proc. Natl. Acad. Sci. USA 90:8000-8004.
75. Lisziewicz, J., D. Sun, A. Lisziewicz, and R. C. Gallo. 1995. Anti-tat gene therapy: a candidate for late-stage AIDS patients. Gene Ther. 2:218-222.
76. Lisziewicz, J., D. Sun, V. Metelev, P. Zamencik, R. C. Gallo, and S. Agrawal. 1993. Long-term treatment of human immunodeficiency virusinfected cells with antisense oligonucleotide phosphorothioates. Proc. Natl. Acad. Sci. USA 90:3860-3864.
77. Lu, S., S. Chaterjee, D. Brar, and K. K. Wong, Jr. 1994. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Ther. 1:267-277.
78. Lu, S., J. S. Santoro, D. H. Fuller, J. R. Haynes, and H. L. Robinson. 1995. Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody-responses in mice. Virology 209:147-154.
79. Maciejewski, J. P., F. F. Weichold, N. S. Young, A. Cara, D. Zella, M. S. Reitz, and R. C. Gallo. 1995. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat. Med. 1:667-673.
80. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Functional dissection of HIV-1 Rev transactivator-derivation of a trans-dominant repressor of Rev function. Cell 58:205-214.
81. Malim, M. H., D. F. McCarn, L. S. Tiley, and B. R. Cullen. 1991. Mutational definition of the human immunodeficiency virus type 1 rev activation domain. J. Virol. 65:4248-4254.
82. Malim, M. H., W. W. Freimuth, J. Liu, T. J, Boyle, H. K. Lyerly, B. R. Cullen, and G. J. Nabel. 1992. Stable expression of transdominant rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176:1197-1201.
83. Manickan, E., Z. Yu, R. j. Rouse, W. S. Wire, and B. T. Rouse. 1995. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27. Viral Immunol. 8:53-61.
84. Marasco, W. A., W. A. Haseltine, and S. Y. Chen. 1993. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. USA 90:7889-7893.
85. Marciniak, R. A., M. A. Garcia-Blanco, and P. A. Sharp. 1990. Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 87:3624-3628.
86. Matsuda, Z., X. Yu, Q.-C. Yu, T. Lee, and M. Essex. 1993. A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:3544-3548.
87. McChesney, M., F. Tanneau, A. Regnault, P. Sansonetti, L. Montagnier, M. P. Kieny, and Y. Riviere. 1990. Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of env amino-terrninal signal sequence. Eur. J. Immunol. 20:215-220.
88. Mhashilkar, A. M., J. Bagley, S. Y. Chen, R. M. Szilvay, D. G. Heiland, and W. A. Marasco. 1995. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 14:1542-1551.
89. Mirabelli, C. K., C. F. Bennett, K. Anderson, and S. T. Crooke. 1991. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anti-Cancer Drug Design 6:647-661.
90. Mizutani, T., N. Kato, M. Hirota, K. Sugiyama, A. Murakami, and K. Shimotohno. 1995. Inhibition of hepatitis C virus replicatio by antisense oligonucleotide in culture cells. Biochem. Biophys. Res. Commun. 212:906-911.
91. Modesti, N., J. Garcia, C. Debouck, M. Peterlin, and R. Gaynor. 1991. Trans-dominant tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol. 3:759-768.
92. Moore, J. P., J. A. McKeating, Y. Huang, A. Ashkenazi, and D. D. Ho. 1992. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66:235-243.
93. Morgan, R. A., D. J. Looney, D. D. Muenchau, F. Wong-Staal, R. C. Gallo, and W. F. Anderson. 1990. Retroviral vectors expressing soluble CD4: a potential gene therapy for AIDS. AIDS Res. Hum. Retroviruses 6:183-191.
94. Morgan, R. A., and W. F. Anderson. 1991. Gene therapy for AIDS, p. 301-308. In A. Kumar (ed.). Advances in molecular biology and targeted treatments for AIDS. Plenum Press, New York, N.Y.
95. Morgan, R. A., G. Baler-Bitterlich, J. A. Ragheb, F. Wong-Staal, R. C. Gallo, and W. F. Anderson. 1994. Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1. AIDS Res. Hum. Retroviruses 10:1507-1515.
96. Morgan, R. A., and B. D. Walker. 1996. Gene transfer for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum. Gene Ther. 7:1281-1306.
97. Morvan, F., H. Porumb, G. Degols, I. Lefebvre, A. Pampon, B. S. Sproat, B. Raynor, C. Malvey, B. Lebleu, and J. L. Imbach. 1993. Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J. Med. Chem. 36:280-287.
98. Mullen, C. A., M. Kilstrup, and R. M. Blaese. 1992. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-flurocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89:33-37.
99. Nabel, G., B. A. Fox, L. Post, C. B. Thompson, and C. Woffendin. 1994. A molecular genetic intervention for AIDS-Effects of a transdominant negative form of Rev. Hum. Gene Ther. 5:79-92.
100. Offensperger, W. B, S. Offensperger, E. Walter, K. Teubner, G. Igloi, H. E. Blum, and W. Gerck. 1993. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 12:1257-1262.
101. Ojwang, J. O., A. Hampel, D. J. Looney, F. Wong-Staal, and J. Rappaport. 1992. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribpzyme. Proc. Natl. Acad. Sci. USA 89:10802-10806.
102. Oldfield, E. H., Z. Ram, K. W. Culver, R. M. Blaese, H. L. Devroom, and W. F. Anderson. 1993. Gene therapy for the treatment of brain tumors using intratumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4:36-39.
103. Orloff, S. L., M. S. Kennedy, A. A. Belperron, P. J. Maddon, and J. S. McDougal. 1993. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HlV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J. Virol. 67:1461-1471.
104. Pagano, P. S., G. Jimenez, N. S. Sung, N. Robb-Traub, and J. C. Lin. 1992. Epstein-Barr viral latency and cell immortilization as targets for antisense oligomers. Ann. N. Y. Acad. Sci. 660:107-116.
105. Pari, G. S., A. K. Field, and J. A. Smith. 1995. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob. Agents Chemother. 39:1157-1161.
106. Poddevin, B., S. Meguenni, I. Elias, M. Vasseur, and M. Blumenfeld. 1994. Improved anti-herpes simplex virus type 1 activity of a phosphodiester antisense oligonucleotide containing a 3′-terminal hairpin-like structure. Antisense Res. Dev. 4:147-154.
107. Ragheb, J. A., P. Bressler, M. Daucher, L. Chiang, M. K. Chuah, T. VandenDriessche, and R. A. Morgan. 1995. Analysis of transdominant mutants of the HIV-1 Rev protein for their ability to inhibit Rev function, HIV-1 replication, and their use as anti-HIV gene therapeutics. AIDS Res. Hum. Retroviruses 11:1343-1353.
108. Reddehase, M. J., F. Weiland, K. Munch, S. Jonjic, A. Lushe, and U. H. Koszinowski. 1985. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that inhibit viral replication during established infection of the lungs. J. Virol. 55:264-273.
109. Reddehase, M. J., W. Mutter, K. Munch, H. J. Burhing, and U. H. Koszinowski. 1987. CDS-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61: 3102-3108.
110. Reusser, P., S. R. Riddell, J. D. Meyers, and P. D. Greenberg. 1991. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373-1380.
111. Rhodes, A., and W. James. 1990. Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA. J. Gen. Virol. 71:1965-1974.
112. Rhodes, A., and W. James. 1991. Inhibition of heterologous strains of HIV by antisense RNA. AIDS 5:145-151.
113. + HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. Hum. Gene Ther. 3:319-338.
114. Riddell, S. R., M. J. Gilbert, and P. D. Greenberg. 1993. CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. Curr. Opin. Immunol. 5:484-492.
115. Riddell, S. R., and P. D. Greenberg. 1995. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13:545-586.
116. Riddell, S. R., M. Rabin, A. P. Geballe, W. J. Brite, and P. D. Greenberg. 1991. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146:2795-2804.
117. Riddell, S. R., K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha, and P. D. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 257:238-247.
118. Rittner, K., and J. Sczakiel. 1991. Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. Nucleic Acids Res. 19:1421-1426.
119. Riviere, Y., F. Tanneau-Slavadori, A. Regnault, O. Lopez, P. Sansonetti, B. Guy, M. P. Kieny, J. J. Fournel, and L. Montagnier. 1989. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J. Virol. 63:2270-2277.
120. Rossi, J. J., D. Elkins, J. A. Zaia, and S. Sullivan. 1992. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. AIDS Res. Hum. Retroviruses 8:183-189.
121. Ruhl, M., M. Himmelspach, G. M. Bahr, F. Hammerschmid, H. Jaksche, B. Wolff, H. Aschauer, G. K. Farrington, H. Probst, D. Bevec, and J. Hauber. 1993. Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 rev activation domain mediating trans-activation. J. Cell Biol. 123:1309-1320.
122. Sarver, N., E. M. Cantin, P. S. Chang, J. A. Zaia, P. A. Ladne. D. A. Stephens, and J. J. Rossi. 1990. Ribozymes'as potential anti-HIV-1 therapeutic agents. Science 247:1222-1225.
123. Schooley, R. T., T. C. Merigan, P. Gaut, M. S. Hirsch, M. Holodniy, T. Flynn, S. Liu, R. E. Byington, S. Henochowicz, and E. Gubish. 1990. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase I-II escalating dosage trial. Ann. Intern. Med. 112:247-253.
124. Schwartz, S., B. K. Felber, and G. N. Pavlakis. 1992. Distinct sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J. Virol. 66:50-159.
125. Schwartz, S., M. Campbell, G. Nasioulas, J. Harrison, B. K. Felber, and G. N. Pavlakis. 1992. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type I results in Rev-independent gag expression. J. Virol. 66:7176-7182.
126. Sczakiel, G., and M. Pawlita. 1991. Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J. Virol. 65:468-472.
127. Sczakiel, G., M. Oppenlander, K. Rittner, and M. Pawlita. 1992. Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis, J. Virol. 66:5576-5581.
128. Shepard, A. A., P. Tolentino, and N. A. DeLuca. 1990. Trans-dominant inhibition of herpes simplex virus transcriptional regulatory protein ICP4 by heterodimer formation. J. Virol. 64:3916-3926.
129. Shoji, Y., J. Shimada, Y. Mizushima, A. Iwasawa, Y. Nakamura, K. Inouye, T. Azuma, M. Sakurai, and T. Nishimura. 1996. Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus. Antimicrob. Agents Chemother. 40:1670-1675.
130. Smith, I. L., R. E. Sekulovich, M. A. Hardwicke, and R. M. Sandri-Goldin. 1991. Mutations in the activation region of herpes simplex virus regulatory protein ICP27 can be trans dominant. J. Virol. 65:3656-3666.
131. Steele, C., P. G. Sacks, K. Adler-Storthz, and E. J. Shillitoe. 1992. Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18. Cancer Res. 52:4706-4711.
132. Steele, C., L. M. Cowsert, and E. J. Shillitoe. 1993. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res. 53:2330-2337.
133. Storey, A., D. Oates, L. Banks, L. Crawford, and T. Crook. 1991. Antisense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res. 19:4109-4114.
134. Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1990. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-608.
135. Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1991. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol. 65:6811-6816.
136. Sullenger, B. A., and T. R. Cech. 1993. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262:1566-1569.
137. Tang, D. C., M. Devit, and S. A. Johnston. 1992. Genetic immunization is a simple method for eliciting and immune response. Nature 356:152-154.
138. Tascon, R. E., M. J. Colston, S. Ragno, E. Stavropolous, D. Gregory, and D. B. Lowrie. 1996. Vaccination against tuberculosis by DNA injection. Nat. Med. 2:888-892.
139. Tokushige, K., T. Wakita, C. Pachuk, D. Moradpour, D. B. Weiner, V. R. Zurawski, and J. R. Wands. 1996. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatol. 24:14-20.
140. Tonkinson, J. L., and C. A. Stein. 1993. Antisense nucleic acids - prospects for antiviral intervention. Antiviral Chem. Chemother. 4:193-199.
141. Traunecker, A., W. Luke, and K. Karjalain. 1988. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 331:84-86.
142. Trono, D., M. B. Feinberg, and D. Baltimore. 1989. HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59: 113-120.
143. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Feigner, V. J. Dwarki, S. H. Gramkowski, R. R. Deck, C. M. DeWitt, A. Friedman, L. A. Hawe, K. R. Leander, D. Martinez, H. C. Perry, J. W. Shiver, D. L. Montgomery, and M. A. Liu. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749.
144. Usman, N., L. Beigelman, and J. A. McSwiggen. 1996. Hammerhead ribozyme engineering. Curr. Opin. Struct. Biol. 1:527-533.
145. VandenDriessche, T., M. K. L. Chuah, and R. A. Morgan. 1994. Gene therapy for acquired immune deficiency syndrome, p. 1-14. In V. T. DeVita, S. Hellman, and S. A. Rosenberg (ed.), AIDS updates, vol. 7. J. B. Lippincott Co., Philadelphia, Pa.
146. + T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. 69:4045-4052.
147. von Knebel Doeberitz, M., C. Rittmuller, H. zur Hausen, and M. Durst. 1992. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int. J. Cancer 51:831-834.
148. von Ruden, T., and E. Gilboa. 1989. Inhibition of human T-cell leukemia virus type I replication in primary human T-cells that express antisense RNA. J. Virol. 63:677-682.
149. Walker, B. D., S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345-348.
150. Walker, B. D., C. Flexner, T. J. Paradis, T. C. Fuller, M. S. Hirsch, R. T. Schooley, and B. Moss. 1988. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 240:64-66.
151. Walker, R. 1993. A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. Hum. Gene Ther. 4:659-680.
152. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogenic bone marrow by transfer of T cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
153. Warner, J. F., C. G. Andersen, L. Laube, D. J. Jolly, K. Townsend, S. Chada, and D. St. Louis. 1991. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res. Hum. Retroviruses 7:645-655.
154. Weber, P. C., J. J. Kenny, and B. Wigdahl. 1992. Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0. J. Gen. Virol. 73:2955-2961.
155. + lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J. Virol. 65:5531-5534.
156. Williams, R. S. 1991. Introduction of foreign genes into tissues of living mice by DNA coated microprojectiles. Proc. Natl. Acad. Sci. USA 88:2726-2730.
157. Wisotzkey, J. D., A. Krizenoskas, S. DiAngelo, and J. W. Krieder. 1993. Cleavage of cottontail rabbit papillomavirus E7 RNA with an anti-E7 ribozyme. Biochem. Biophys. Res. Commun. 192:833-839.
158. Woffendin, C., Z.-Y. Yang, R. Udaykumar, L. Xu, N. S. Yang, M. J. Sheeny, and G. J. Nabel. 1994. Nonviral and viral delivery of human immunodeficiency virus protective gene into primary human T cells. Proc. Natl. Acad. Sci. USA 91:11581-11585.
159. Wolff, J. A., R. W. Malone, P. Williams, W. Chong, G. Ascadi, A. Jani, and P. L. Felgner. 1990. Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468.
160. Wong, Y. F., T. K. Chung, T. H. Cheung, S. K. Lam, and A. M. Chang. 1994. Effects of human papillomavirus type-specific antisense oligonucleotides on cervical cancer cells containing papillomavirus. Med. Oncol. 11:149-151.
161. Wu, G. Y., and C. H. Wu. 1992. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267:12436-12439.
162. Yamada, O., M. Yu, J. K. Yee, G. Kraus, D. Looney, and F. Wong-Staal. 1994. Intracellular immunization of human cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther. 1:38-45.
163. Yao, G. Q., S. Grill, W. Egan, and Y. C. Cheng. 1993. Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification. Antimicrob. Agents Chemother. 37:1420-1425.
164. Yap, I., R. Guan, and S. H. Chan. 1994. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non-pre-S containing vaccines. J. Gastroenterol. Hepatol. 10:51-55.
165. Yu, M., J. Ojwang, O. Yamada, A. Hampel, J. Rapapport, D. Looney, and F. Wong-Staal. 1993. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:6340-6344.
166. Yu, X., X. Yuan, Z. Matsuda, T. H. Lee, and M. Essex. 1992. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J. Virol. 66:4966-4971.